Skip to content
    HUM
    Earnings call· Dec 2024(Q4 FY24)

    HUMANA INC HUM

    Feb 11, 2025 Source

    Executive summary

    Humana Q4 FY24 — Reaffirms 2025 Outlook Amidst MA Repricing and Stars Recovery Focus

    Humana reaffirmed its 2025 outlook, emphasizing a commitment to achieving a 3% individual MA margin despite ongoing industry volatility and regulatory headwinds. The company is focused on operational improvements across product experience, clinical excellence, and back-office efficiency, particularly in Stars ratings recovery and Medicaid growth, while prudently managing its balance sheet. New leadership aims to bring fresh perspectives to navigate this transition period.

    Highlights

    5
    • 2024 adjusted EPS was in line with initial guidance, including investments in Stars and growth.

    • Achieved nearly 5% membership growth in 2024 despite repricing products to reflect elevated medical cost trends.

    • Improved operating expense ratio by 40 basis points in 2024 through efficiency initiatives.

    • Closed 650,000 care gaps in Q4 2024, demonstrating significant operational progress for Stars performance.

    • Medicaid business is emerging as a strong scale business, with expected member growth of 175,000-250,000 in 2025.

    Concerns

    5
    • Experienced membership losses, particularly in the D-SNP space, though largely consistent with strategy.

    • Uncertainty around 2027 Stars thresholds makes returning to an industry-leading position "tight".

    • Group MA market is expected to face pressure in 2025 due to long-term rate guarantee contracts.

    • 45% of 2025 Medicaid members are in states with less than 3 years of experience, leading to an initial drag on earnings.

    • The preliminary MA rate notice's forward-looking component likely underestimates future trend.

    Guidance & targets

    5
    CategoryTargetConfidence
    Individual MA Margin
    at least a 3%
    high materiality
    High
    2025 Earnings Seasonality
    60% to 65%
    medium materiality
    High
    Medicaid Member Growth
    175,000, 250,000
    medium materiality
    High
    Part D Member Growth
    roughly 200,000 members
    medium materiality
    High
    Group MA Margin
    improvement
    medium materiality
    Medium

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Individual MA
    Membership growth in 2024 was achieved despite repricing products for elevated medical cost trends. The company's strategy involved shedding unprofitable plans and resetting expectations in lower-margin plans. D-SNP losses were higher than expected, with 30,000 members lost due to redeterminations, but the company is comfortable with improving its positioning in this space.
    Membership growth 2024: nearly 5%D-SNP membership losses: higher than expectedD-SNP losses due to redeterminations: 30,000 members
    nearly 5%
    Medicaid
    The Medicaid business is emerging as a strong scale business with meaningful earnings potential. Member growth in 2025 is expected from new states like Virginia and additional allocations in Kentucky. While modest margin improvements are expected in 2025, 45% of members are in states with less than three years of experience, leading to an initial drag on earnings. Florida, the most mature state, is performing at expected margin levels.
    Member growth 2025: 175,000-250,000Members in states with <3 years experience 2025: 45%2025 rates known: 75% of revenue
    modest improvements in margin
    Group MA
    The Group MA market is less mature than the individual market, with historical long-term rate guarantee contracts. This is changing, but will take time to flow through financials. Pressure is expected in 2025, with margin improvement anticipated in 2026 as long-term contracts come up for renewal.
    Members: roughly 0.5 million
    some more pressure in '25
    Part D (PDP)
    The company is pricing for margin given the additional risk of IRA and is participating in the premium stabilization demonstration. Member growth of approximately 200,000 is expected in 2025, driven by competitive dynamics and strong broker relationships. Early claims data confirms expectations for utilization and pricing strategy.
    Member growth 2025: roughly 200,000 members (vs. prior flat expectation)Participation: premium stabilization demonstration
    pricing for margin

    Operational metrics

    7
    Operating expense ratio improvement
    40improved
    2024

    Improvement was achieved through care model optimization, unified shipping, outsourcing, and streamlined internal distribution.

    Care gaps closed
    650,000significant improvement from September
    Q4 2024

    This progress was made to improve Stars performance for the 2027 payment year.

    Earnings seasonality
    60% to 65%significant shift from last year
    Q1 FY25

    This shift is driven by IRA changes, planned benefit design changes (including deductibles), favorable calendar, and timing of incremental investments.

    Specialty drug spend
    elevated, relatively stablelooks very much the way it has looked for the last couple of quarters
    Q4 2024

    Management feels that where they have priced and forecasted is appropriate given current trends.

    Incremental investments
    a few hundred million
    2025

    These investments are across initiatives designed to improve operating performance, focusing on Stars, clinical excellence, and membership strategies.

    Medicaid members in immature states
    45%
    2025

    This contributes to the J-curve effect, where initial years are a drag on earnings for new Medicaid contracts.

    Medicaid 2025 rates known
    75%
    2025

    The remaining 25% are in a 'pre-draft state' with less clarity.

    Industry KPIs

    8
    MetricValueDetails
    Utilization trendsnormalized trend
    Stars rate environmenttight
    Medical loss care ratio
    Pharmacy scripts specialty
    Membership covered lives by linenearly 5%%
    Segment revenue operating income
    Adjusted EPS EBITDA leverage guidancein line with initial guidance
    Medical cost trend vs pricing assumptionnormalized trend

    Risks & headwinds

    7
    Stars Threshold Uncertainty2027

    tight for 2027 payment year

    Mitigation: Significant operational progress in Q4 2024 (closed 650,000 care gaps); full year runway for operating improvements in measurement year 2025 (bonus year 2028).

    Elevated Medical Cost Trend2024

    elevated in 2024

    Mitigation: Repricing products and shedding unprofitable plans; forecasting normalized trend for 2025.

    Higher-than-expected D-SNP Attrition2025

    30,000 members lost due to redeterminations

    Mitigation: Learning from experience, implementing pilots, and leveraging Medicaid footprint for future integration.

    Group MA Margin Pressure2025

    some more pressure in '25

    Mitigation: Expect margin improvement in 2026 through pricing actions as long-term contracts renew.

    Medicaid J-Curve Effect2025 and beyond

    45% of 2025 members in states with <3 years experience, initial years are a drag on earnings

    Mitigation: Focus on maturation of new contracts, leveraging proof points from mature states like Florida.

    IRA Impact on Part D2025

    increased plan liability, shifts seasonality

    Mitigation: Pricing for margin, participating in the premium stabilization demonstration, monitoring early claims data.

    MA Rate Notice Underestimation of Trend2025 and beyond

    forward-looking component probably underestimates what forward-looking trend is likely to be

    Mitigation: Monitoring developments over the next few months; ongoing engagement with CMS.

    What to watch in Q1 FY25

    5

    Stars Performance for 2027

    next quarter (for threshold clarity), 2027 (for payment year)
    Currenttight and dependent on final thresholds
    Targetreturn to industry-leading position

    Why it matters

    Stars ratings directly impact MA profitability and competitive positioning, making their recovery crucial for the investment thesis.

    the question, of course, is will these steps that we've taken, be enough to return us to an industry-leading position in 2027? As we acknowledge back in October, it will be tight, and ultimately, it will depend on the final thresholds.

    Q&A highlights

    5

    Break down the levers of the 2025 MLR increase, including base assumptions, cost trend, IRA changes, and D-SNP loss impact.

    Celeste Mellet detailed MLR improvement drivers (MA plan exits, benefit adjustments, favorable calendar) and increase drivers (Medicaid growth, IRA impact, incremental investments). She noted D-SNP losses helped on the margin but were not the primary driver of improvement.

    The majority of the improvement is driven from the MA plan exits, which all had very high benefit ratios. We also made other adjustments to our benefits in our remaining plans, which also improved the ratio.

    asked by Ann Hynes · answered by Celeste Mellet

    2 min read6 chapters

    Detailed Narrative

    01

    New Leadership and Strategic Levers

    Humana introduced new key executives, including Celeste Mellet as CFO, Michelle O'Hara as CHRO, and Japan Mehta as CIO, aiming to bring fresh perspectives to navigate industry transitions. CEO Jim Rechtin outlined four strategic levers: product experience, clinical excellence, efficient back office, and capital allocation, as fundamental drivers for the business's future success and value creation.

    02

    Medicare Advantage Strategy and Membership Mix

    The company's 2024 strategy involved repricing Medicare Advantage products to account for elevated medical cost trends, resulting in the shedding of unprofitable plans and resetting expectations in lower-margin offerings. While this led to some membership losses, particularly in the D-SNP space, management views these as largely consistent with their goal of attracting a new member mix focused on sustainable long-term value.

    03

    Stars Performance and Clinical Excellence

    Humana made significant operational progress in Q4 2024 by closing 650,000 care gaps, a key initiative to improve Stars performance. While the path to an industry-leading Stars position in 2027 remains "tight" and dependent on final thresholds, the company is fully focused on measurement year 2025 (bonus year 2028), leveraging a full year of runway for operating improvements.

    04

    Operating Efficiency and Cost Structure

    In 2024, Humana improved its operating expense ratio by 40 basis points through various initiatives, including care model optimization, unified shipping, outsourcing noncore capabilities, and streamlining internal distribution. Management believes further efficiencies are achievable and plans to communicate a path for additional improvements in the coming months, aiming for a more flexible and variable cost structure.

    05

    Medicaid Growth and Profitability

    Humana's Medicaid business is expanding, with an expected member growth of 175,000-250,000 in 2025, driven by new state wins (e.g., Virginia) and additional allocations (e.g., Kentucky). While 45% of 2025 Medicaid members are in states with less than three years of experience, leading to an initial drag on earnings, the performance of mature states like Florida provides a proof point for future margin recovery.

    06

    Industry Context and MA Value Proposition

    Management reiterated Medicare Advantage's critical role in the U.S. healthcare system, highlighting its ability to deliver better outcomes, operate more efficiently, and provide more affordable access compared to original Medicare. The company expressed openness to partnering constructively to improve the MA program and is internally focused on simplifying healthcare navigation for its members.

    AI-generated summary of the company’s earnings call. Not investment advice.